A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

NCT01299480 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
1714
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer